Velimir A. Luketic

25.0k citations

176 papers · 14.2k indexed · 6 hit papers · h-index 58

Epidemiology top 0.05%
Hepatology top 0.02%
Surgery top 0.5%
Endocrinology, Diabetes and Metabolism top 0.5%
Molecular Biology top 5%

Co-authors: Arun J. Sanyal Richard K. Sterling Mitchell L. Shiffman Melissa J. Contos Robert A. Fisher Faridoddin Mirshahi John N. Clore Carol Sargeant
Topics: Liver Disease Diagnosis and Treatment (114 papers)Liver Disease and Transplantation (72 papers)Hepatitis C virus research (49 papers)
Cited by: Hepatology Epidemiology Endocrinology, Diabetes and Metabolism
Journals: The Journal of Experimental Medicine Annals of Internal Medicine Gastroenterology
Partner nations: United States United Kingdom Canada

In The Last Decade

Velimir A. Luketic

173 papers receiving 13.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities

2001 1.7k citations Arun J. Sanyal, Faridoddin Mirshahi et al. profile →
Clinical and Histologic Spectrum of Nonalcoholic Fatty Liver Disease Associated With Normal Alt Values

2003 909 citations Melissa J. Contos, Carol Sargeant et al. Hepatology profile →
Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression

2008 557 citations Prem Puri, Melissa J. Contos et al. Hepatology profile →
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis #

2009 478 citations Kris V. Kowdley, Velimir A. Luketic et al. Hepatology profile →
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid

2014 421 citations Gideon M. Hirschfield, Andrew L. Mason et al. profile →
The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids

2017 325 citations Prem Puri, Kalyani Daita et al. Hepatology profile →

Peers

Countries citing papers authored by Velimir A. Luketic

Since Specialization

Citations

This map shows the geographic impact of Velimir A. Luketic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Velimir A. Luketic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Velimir A. Luketic more than expected).

Fields of papers citing papers by Velimir A. Luketic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Velimir A. Luketic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Velimir A. Luketic. The network helps show where Velimir A. Luketic may publish in the future.

Co-authorship network of co-authors of Velimir A. Luketic

This figure shows the co-authorship network connecting the top 25 collaborators of Velimir A. Luketic. A scholar is included among the top collaborators of Velimir A. Luketic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Velimir A. Luketic. Velimir A. Luketic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A double-blind randomized placebo-controlled trial of albumin in outpatients with hepatic encephalopathy: HEAL study 2022 ·Journal of Hepatology ·Andrew Fagan,Edith Gavis,(unknown),(unknown),Brian Davis,Prem Puri,Richard K. Sterling,Velimir A. Luketic,Hannah Lee,Scott Matherly,Arun J. Sanyal,R. Todd Stravitz,Vaishali Patel,Mohammad Shadab Siddiqui,Amon Asgharpour,Michael Fuchs,Leroy R. Thacker,Jasmohan S. Bajaj	39
2	A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA 2021 ·Journal of Hepatology ·Jörn M. Schattenberg,Albert Parés,Kris V. Kowdley,Michael A. Heneghan,Stephen H. Caldwell,Daniel S. Pratt,Alan Bonder,Gideon M. Hirschfield,Cynthia Levy,John M. Vierling,David Jones,Anne Tailleux,Bart Staels,S. Megnien,Rémy Hanf,(unknown),P Birman,Velimir A. Luketic	125
3	Association Between Lipoprotein Particles and Atherosclerotic Events in Nonalcoholic Fatty Liver Disease 2020 ·Clinical Gastroenterology and Hepatology ·Samarth Patel,Mohammad Siddiqui,(unknown),Emily Zhang,Emily Lee,Steven S. Shen,(unknown),(unknown),Sherry Boyett,Michael O. Idowu,Arun J. Sanyal,Velimir A. Luketic,Mohammad Shadab Siddiqui	16
4	Treatment of HCV in the Department of Corrections in the Era of Oral Medications 2018 ·Journal of Correctional Health Care ·Richard K. Sterling,(unknown),(unknown),(unknown),Carolyn Driscoll,(unknown),(unknown),Scott Matherly,Mohammad Shadab Siddiqui,Velimir A. Luketic,R. Todd Stravitz,Prem Puri,Hannah Lee,Paula G. Smith,Vaishali Patel,Arun J. Sanyal	30
5	The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acidsbreakdown → 2017 ·Hepatology ·Prem Puri,Kalyani Daita,Andrew Joyce,Faridoddin Mirshahi,Prasanna K. Santhekadur,Sophie C. Cazanave,Velimir A. Luketic,Mohammad Shadab Siddiqui,Sherry Boyett,Hae‐Ki Min,Divya P. Kumar,Rohit Kohli,Huiping Zhou,Phillip B. Hylemon,Melissa J. Contos,Michael O. Idowu,Arun J. Sanyal	325
6	Nonalcoholic Steatohepatitis (NASH) Is Associated with a Decline in Pancreatic Beta Cell (β-Cell) Function 2015 ·Digestive Diseases and Sciences ·Mohammad Shadab Siddiqui,(unknown),Velimir A. Luketic,Sherry Boyett,Michael O. Idowu,Kavish R. Patidar,Prem Puri,Scott Matherly,Richard T. Stravitz,Richard K. Sterling,Arun J. Sanyal	29
7	Severity of Nonalcoholic Fatty Liver Disease and Progression to Cirrhosis Are Associated With Atherogenic Lipoprotein Profile 2014 ·Clinical Gastroenterology and Hepatology ·Mohammad Shadab Siddiqui,Michael Fuchs,Michael O. Idowu,Velimir A. Luketic,Sherry Boyett,Carol Sargeant,Richard T. Stravitz,Prem Puri,Scott Matherly,Richard K. Sterling,Melissa J. Contos,Arun J. Sanyal	174
8	28 AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID AS MONOTHERAPY IN PBC 2011 ·Journal of Hepatology ·Kris V. Kowdley,(unknown),Velimir A. Luketic,Robert Chapman,A.K. Burroughs,Gideon M. Hirschfield,Raoul Poupon,Christoph Schramm,(unknown),C Rust,Albert Parés,Andrew L. Mason,(unknown),(unknown),O. Böhm,Erin Castelloe,Mark Pruzanski,Д. А. Шапиро	47
9	Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States 2007 ·Hepatology ·Marion G. Peters,Adrian M. Di Bisceglie,Kris V. Kowdley,(unknown),Velimir A. Luketic,Santiago J. Muñoz,Guadalupe García–Tsao,Thomas Boyer,John R. Lake,Maurizio Bonacini,Burton Combes	50
10	Multimodality Therapy and Liver Transplantation in Patients With Cirrhosis and Hepatocellular Carcinoma: 6 Years, Single-Center Experience 2007 ·Transplantation Proceedings ·Daniel G. Maluf,R. Todd Stravitz,Brett Williams,Adrian Cotterell,Valeria R. Mas,Douglas M. Heuman,Velimir A. Luketic,Mitchell L. Shiffman,Richard K. Sterling,M. P. Posner,Robert A. Fisher	13
11	Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease 2005 ·Liver Transplantation ·Rolland C. Dickson,Norah A. Terrault,Michael B. Ishitani,K. Rajender Reddy,Patricia A. Sheiner,Velimir A. Luketic,Consuelo Soldevila‐Pico,Michael Fried,Donald M. Jensen,Robert S. Brown,Gary Horwith,Richard C. Brundage,Anna S. Lok	33
12	Prolonged Follow-Up of Patients in the U.S. Multicenter Trial of Ursodeoxycholic Acid for Primary Biliary Cirrhosis 2004 ·The American Journal of Gastroenterology ·Burton Combes,Velimir A. Luketic,Marion G. Peters,Rowen K. Zetterman,Guadalupe García–Tsao,Santiago J. Muñoz,Dan-Yu Lin,(unknown),Robert L. Carithers	30
13	The Clinical Spectrum of Hepatitis C Virus in HIV Coinfection 2003 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Richard K. Sterling,Melissa J. Contos,Arun J. Sanyal,Velimir A. Luketic,R. Todd Stravitz,Mary Sweig Wilson,A. Scott Mills,Mitchell L. Shiffman	37
14	Clinical and Histologic Spectrum of Nonalcoholic Fatty Liver Disease Associated With Normal Alt Valuesbreakdown → 2003 ·Hepatology ·(unknown),Melissa J. Contos,(unknown),Carol Sargeant,Robert A. Fisher,Velimir A. Luketic,Richard K. Sterling,Mitchell L. Shiffman,Richard T. Stravitz,Arun J. Sanyal	909
15	Comparison of Three Commercially Available Assays for Hcv Rna Using The International Unit Standard: Implications for Management of Patients With Chronic Hepatitis C Virus Infection in Clinical Practice 2003 ·The American Journal of Gastroenterology ·Mitchell L. Shiffman,Andrea Ferreira‐Gonzalez,K. Rajender Reddy,Richard K. Sterling,Velimir A. Luketic,Todd R. Stravitz,Arun J. Sanyal,Carleton T. Garrett,Maria de Medina,Eugene R. Schiff	21
16	Identification of HLA-A2–restricted CD8+ Cytotoxic T Cell Responses in Primary Biliary Cirrhosis 2002 ·The Journal of Experimental Medicine ·Hiroto Kita,Zhe‐Xiong Lian,Judy Van de Water,Xiaosong He,Shuji Matsumura,Marshall Kaplan,Velimir A. Luketic,Ross L. Coppel,Aftab A. Ansari,M. Eric Gershwin	229
17	Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis 2001 ·Liver Transplantation ·Melissa J. Contos,(unknown),Richard K. Sterling,Velimir A. Luketic,Mitchell L. Shiffman,A. Scott Mills,Robert A. Fisher,J. M. Ham,Arun J. Sanyal	290
18	A Randomized, Controlled Trial to Determine Whether Continued Ribavirin Monotherapy in Hepatitis C Virus–Infected Patients Who Responded to Interferon‐Ribavirin Combination Therapy Will Enhance Sustained Virologic Response 2001 ·The Journal of Infectious Diseases ·Mitchell L. Shiffman,Charlotte M. Hofmann,Richard K. Sterling,Velimir A. Luketic,Melissa J. Contos,Arun J. Sanyal	25
19	RIGHT LOBE LIVING DONOR LIVER TRANSPLANTATION 1999 ·Transplantation ·Amadeo Marcos,Robert A. Fisher,J. M. Ham,Mitchell L. Shiffman,Arun J. Sanyal,Velimir A. Luketic,Richard K. Sterling,Marc P. Posner	340
20	Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C 1997 ·Hepatology ·Mitchell L. Shiffman,Charlotte M. Hofmann,Elizabeth Thompson,Andrea Ferreira‐Gonzalez,Melissa J. Contos,Abraham Koshy,Velimir A. Luketic,Arun J. Sanyal,A. Scott Mills,Carleton T. Garrett	134

About Velimir A. Luketic

Velimir A. Luketic is a scholar working on Hepatology, Epidemiology and Transplantation, having authored 176 papers that have together received 14.2k indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (114 papers), Liver Disease and Transplantation (72 papers) and Hepatitis C virus research (49 papers). The work is most often cited by research in Hepatology (9.1k citations), Epidemiology (10.5k citations) and Endocrinology, Diabetes and Metabolism (2.3k citations). Velimir A. Luketic has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Arun J. Sanyal, Richard K. Sterling, Mitchell L. Shiffman, Melissa J. Contos, Robert A. Fisher, Faridoddin Mirshahi, John N. Clore, Carol Sargeant, Prem Puri and A. Scott Mills. Their work appears in journals such as The Journal of Experimental Medicine, Annals of Internal Medicine and Gastroenterology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact